Fidel Rubagumya, MD


Dr. Fidel Rubagumya received his medical degree from the National University of Rwanda. He completed his medical internship at Butaro Cancer Center of Excellence and received his Master of Medicine in Clinical Oncology from the Muhimbili University of Health and Allied Sciences.

Dr. Rubagumya served as a General Practitioner at Butaro Cancer Center of Excellence before joining Muhimbili University of Health and Allied Sciences. While Dr. Rubagumya treats all cancers, he has special interest in head and neck cancers, gynecological, and gastro-intestinal cancers, as well as cancers that affect special groups. He also has a keen interest in end of life care and global oncology.

Dr. Rubagumya is an enthusiastic cancer advocate. He has been involved in many cancer control activities in Rwanda and internationally. Dr. Rubagumya is the Founder of Rwanda Children’s Cancer Relief (RCCR), an organization that raises awareness on childhood cancers and advocates for children living with cancer and their families. Before founding RCCR, Dr. Rubagumya was actively involved in breast cancer advocacy work with Breast Cancer Initiative East Africa (BCIEA). He is a member of numerous cancer organizations both locally and internationally. Dr. Rubagumya is a recipient of many prestigious awards including the American Cancer Society Global Scholar award, the International Development and Education Award (IDEA) of American Society of Clinical Oncology, and both the International Cancer Research Technology Transfer Fellowship (ICRETT) and the African Cancer Fellowship awards of Union for International Cancer Control (UICC) and Africa Cancer Leader Institute award of African Organization of Cancer Research and Training (AORTIC), among others.

Dr. Rubagumya’s research focuses on integrating technological advances like mobile applications to improve cancer care in low-resource settings. He was awarded the ASCO International Innovation Grant for his mobile application used to help increase early detection of skin cancers in people with albinism.